{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:09:16Z","timestamp":1790104156942,"version":"4.0.1"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03346-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:33:06Z","timestamp":1772065986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-765X","authenticated-orcid":false,"given":"Heena","family":"Maithania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-1845","authenticated-orcid":false,"given":"Rijo","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3255-6267","authenticated-orcid":false,"given":"Raghunandhan","family":"Painoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-8337","authenticated-orcid":false,"given":"Jasmin","family":"Monpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-7105","authenticated-orcid":false,"given":"Shankar","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-9628","authenticated-orcid":false,"given":"Rahul","family":"Kalhapure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"1","key":"3346_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2310\/7290.2010.00008","volume":"9","author":"JP Holland","year":"2010","unstructured":"Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010;9(1):1\u201320.","journal-title":"Mol Imaging."},{"key":"3346_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jlcr.3196","volume":"57","author":"S Pascu","year":"2014","unstructured":"Pascu S, Dilworth J. Recent developments in PET and SPECT imaging. J Labelled Comp Radiopharm. 2014;57:191\u20134. https:\/\/doi.org\/10.1002\/jlcr.3196.","journal-title":"J Labelled Comp Radiopharm"},{"key":"3346_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/JU.0000000000002326","volume":"207","author":"O Sartor","year":"2022","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Re: lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. J Urol. 2022;207:467\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000002326.","journal-title":"J Urol"},{"key":"3346_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/nejmoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franz\u00e9n L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland \u00d8S, Sartor O. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/nejmoa1213755.","journal-title":"N Engl J Med"},{"key":"3346_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, Dorisio TMO, Baum RP, Kulkarni HR, Caplin M, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Mora J, Berlin J, Grande E, Reed N, Seregni E, Sierra ML, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2018;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"3346_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping Thang S, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"3346_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86159-9","volume":"15","author":"A Golzaryan","year":"2025","unstructured":"Golzaryan A, Soltani M, Moradi Kashkooli F, Saboury B, Rahmim A. Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling. Sci Rep. 2025;15: 4052. https:\/\/doi.org\/10.1038\/s41598-025-86159-9.","journal-title":"Sci Rep"},{"key":"3346_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.11909\/j.issn.1671-5411.2014.03.005","volume":"11","author":"ZH Sun","year":"2014","unstructured":"Sun ZH, Rashmizal H, Xu L. Molecular imaging of plaques in coronary arteries with PET and SPECT. J Geriatr Cardiol. 2014;11:259\u201373. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2014.03.005.","journal-title":"J Geriatr Cardiol"},{"key":"3346_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102765","volume":"12","author":"A Doctor","year":"2020","unstructured":"Doctor A, Seifert V, Ullrich M, Hauser S, Pietzsch J. Three-dimensional cell culture systems in radiopharmaceutical cancer research. Cancers (Basel). 2020;12:1\u201328. https:\/\/doi.org\/10.3390\/cancers12102765.","journal-title":"Cancers (Basel)"},{"key":"3346_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","volume":"115","author":"KE Salerno","year":"2023","unstructured":"Salerno KE, Roy S, Ribaudo C, Fisher T, Patel RB, Mena E, Escorcia FE. A primer on radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys. 2023;115:48\u201359. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3346_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2022.889640","volume":"9","author":"JY Lee","year":"2022","unstructured":"Lee JY, Chae JH, Hur MG, Yang SD, Kong YB, Lee J, Ju JS, Choi PS, Park JH. Theragnostic 64Cu\/67Cu radioisotopes production with RFT-30 cyclotron. Front Med (Lausanne). 2022;9:1\u20137. https:\/\/doi.org\/10.3389\/fmed.2022.889640.","journal-title":"Front Med (Lausanne)"},{"key":"3346_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-024-00281-z","author":"E Moya","year":"2024","unstructured":"Moya E, Cerrato C, Bedoya LM, Guerra JA. Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation? EJNMMI Radiopharm Chem. 2024. https:\/\/doi.org\/10.1186\/s41181-024-00281-z.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR13","unstructured":"Coherent Market Insights. Global radiopharmaceuticals in nuclear medicine market to surpass US$10.6 billion by 2026. Market research report. Coherent Market Insights; 2019."},{"key":"3346_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-023-01627-0","volume":"29","author":"S Dhoundiyal","year":"2024","unstructured":"Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, Mishra N, Taghizadeh-Hesary F. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29:1\u201319. https:\/\/doi.org\/10.1186\/s40001-023-01627-0.","journal-title":"Eur J Med Res"},{"key":"3346_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nucmedbio.2021.06.008","volume":"92","author":"A Duatti","year":"2021","unstructured":"Duatti A. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. Nucl Med Biol. 2021;92:202\u201316. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.008.","journal-title":"Nucl Med Biol."},{"key":"3346_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023;73:255\u201374. https:\/\/doi.org\/10.3322\/caac.21768.","journal-title":"CA Cancer J Clin"},{"key":"3346_CR17","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1007\/s00259-021-05672-x","volume":"49","author":"X Wang","year":"2022","unstructured":"Wang X, Zhou M, Chen B, Liu H, Fang J, Xiang S, Hu S, Zhang X. Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. Eur J Nucl Med Mol Imaging. 2022;49:2584\u201394. https:\/\/doi.org\/10.1007\/s00259-021-05672-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3346_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.apsb.2021.09.016","volume":"12","author":"K Hu","year":"2022","unstructured":"Hu K, Wu W, Xie L, Geng H, Zhang Y, Hanyu M, Zhang L, Liu Y, Nagatsu K, Suzuki H, Guo J, Wu Y, Li Z, Wang F, Zhang M. Whole-body PET tracking of a D-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Acta Pharm Sin B. 2022;12:1363\u201376. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.016.","journal-title":"Acta Pharm Sin B"},{"key":"3346_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1021\/acs.molpharmaceut.1c00694","volume":"19","author":"H Liu","year":"2022","unstructured":"Liu H, Hu M, Deng J, Zhao Y, Peng D, Feng Y, Wang L, Chen Y, Qiu L. A novel small cyclic peptide-based 68Ga-radiotracer for positron emission tomography imaging of PD-L1 expression in tumors. Mol Pharm. 2022;19:138\u201347. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00694.","journal-title":"Mol Pharm"},{"key":"3346_CR20","doi-asserted-by":"publisher","first-page":"263S","DOI":"10.2967\/jnumed.120.254532","volume":"61","author":"WA Weber","year":"2020","unstructured":"Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schoder H, Siegel BA, Strauss HW. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 2020;61:263S-272S. https:\/\/doi.org\/10.2967\/jnumed.120.254532.","journal-title":"J Nucl Med"},{"key":"3346_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nucmedbio.2019.01.006","volume":"70","author":"M Brandt","year":"2019","unstructured":"Brandt M, Cardinale J, Giammei C, Guarrochena X, Happl B, Jouini N, Mindt TL. Mini-review: targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders. Nucl Med Biol. 2019;70:46\u201352. https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.01.006.","journal-title":"Nucl Med Biol"},{"key":"3346_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-016-0004-6","volume":"1","author":"J Koziorowski","year":"2016","unstructured":"Koziorowski J, Behe M, Decristoforo C, Ballinger J, Elsinga P, Ferrari V, Kolenc Peitl P, Todde S, Mindt TL. Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2016;1:1\u20136. https:\/\/doi.org\/10.1186\/s41181-016-0004-6.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"3346_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051312","volume":"12","author":"J Lau","year":"2020","unstructured":"Lau J, Rousseau E, Kwon D, Lin KS, B\u00e9nard F, Chen X. Insight into the development of PET radiopharmaceuticals for oncology. Cancers (Basel). 2020;12(5): 1312. https:\/\/doi.org\/10.3390\/cancers12051312.","journal-title":"Cancers (Basel)"},{"key":"3346_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/app9122526","volume":"9","author":"A Boschi","year":"2019","unstructured":"Boschi A, Uccelli L, Martini P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Appl Sci. 2019;9: 2526. https:\/\/doi.org\/10.3390\/app9122526.","journal-title":"Appl Sci"},{"key":"3346_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13346-019-00670-x","volume":"10","author":"HV Maithania","year":"2020","unstructured":"Maithania HV, Mohanty BS, Chaudhari PR, Samad A, Devarajan PV. Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles. Drug Deliv Transl Res. 2020;10:159\u201367. https:\/\/doi.org\/10.1007\/s13346-019-00670-x.","journal-title":"Drug Deliv Transl Res"},{"key":"3346_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijpharm.2004.09.022","volume":"289","author":"T Banerjee","year":"2005","unstructured":"Banerjee T, Singh AK, Sharma RK, Maitra AN. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Int J Pharm. 2005;289:189\u201395. https:\/\/doi.org\/10.1016\/j.ijpharm.2004.09.022.","journal-title":"Int J Pharm"},{"key":"3346_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2016.08.016","volume":"44","author":"SM Qaim","year":"2017","unstructured":"Qaim SM. Nuclear data for production and medical application of radionuclides: present status and future needs. Nucl Med Biol. 2017;44:31\u201349. https:\/\/doi.org\/10.1016\/j.nucmedbio.2016.08.016.","journal-title":"Nucl Med Biol"},{"key":"3346_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1053\/j.semnuclmed.2019.07.001","volume":"49","author":"K Vermeulen","year":"2019","unstructured":"Vermeulen K, Vandamme M, Bormans G, Cleeren F. Design and challenges of radiopharmaceuticals. Semin Nucl Med. 2019;49:339\u201356. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.07.001.","journal-title":"Semin Nucl Med"},{"key":"3346_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02041-6","author":"S Zhang","year":"2025","unstructured":"Zhang S, Wang X, Gao X, Chen X, Li L, Li G, Liu C, Miao Y, Wang R, Hu K. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther. 2025. https:\/\/doi.org\/10.1038\/s41392-024-02041-6.","journal-title":"Signal Transduct Target Ther"},{"key":"3346_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0104-4","author":"N Pandit-Taskar","year":"2015","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Divgi CR, Wills EA, Schwartz L, G\u00f6nen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015. https:\/\/doi.org\/10.1186\/s13550-015-0104-4.","journal-title":"EJNMMI Res"},{"key":"3346_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095023","author":"G Cri\u0219an","year":"2022","unstructured":"Cri\u0219an G, Moldovean\u2010cioroianu NS, Timaru DG, Andrie\u0219 G, C\u0103inap C, Chi\u0219 V. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23095023.","journal-title":"Int J Mol Sci"},{"key":"3346_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.675221","volume":"8","author":"M de Van Voor","year":"2021","unstructured":"de Van Voor M, Duchemin C, Heinke R, Lambert L, Chevallay E, Schneider T, Van Stenis M, Cocolios TE, Cardinaels T, Ponsard B, Ooms M, Stora T, Burgoyne AR. Production of Sm-153 with very high specific activity for targeted radionuclide therapy. Front Med (Lausanne). 2021;8:1\u20139. https:\/\/doi.org\/10.3389\/fmed.2021.675221.","journal-title":"Front Med (Lausanne)"},{"key":"3346_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-019-0246-y","author":"O Kochebina","year":"2019","unstructured":"Kochebina O, Halty A, Taleb J, Kryza D, Janier M, Sadr AB, Baudier T, Rit S, Sarrut D. In vivo gadolinium nanoparticle quantification with SPECT\/CT. EJNMMI Phys. 2019. https:\/\/doi.org\/10.1186\/s40658-019-0246-y.","journal-title":"EJNMMI Phys"},{"key":"3346_CR34","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/eurheartj\/ehr367","volume":"33","author":"O Gaemperli","year":"2012","unstructured":"Gaemperli O, Shalhoub J, Owen DRJ, Lamare F, Johansson S, Fouladi N, Davies AH, Rimoldi OE, Camici PG. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography\/computed tomography. Eur Heart J. 2012;33:1902\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehr367.","journal-title":"Eur Heart J"},{"key":"3346_CR35","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jacc.2014.05.069","volume":"64","author":"I Danad","year":"2014","unstructured":"Danad I, Uusitalo V, Kero T, Saraste A, Raijmakers PG, Lammertsma AA, Heymans MW, Kajander SA, Pietil\u00e4 M, James S, S\u00f6rensen J, Knaapen P, Knuuti J. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative [15O]H2O PET imaging. J Am Coll Cardiol. 2014;64:1464\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2014.05.069.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3346_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0883-2889(87)90122-5","volume":"38","author":"JC Clark","year":"1987","unstructured":"Clark JC, Crouzel C, Meyer GJ, Strijckmans K. Current methodology for oxygen-15 production for clinical use. Int J Radiat Appl Instrum A. 1987;38(8):597\u2013600. https:\/\/doi.org\/10.1016\/0883-2889(87)90122-5.","journal-title":"Int J Radiat Appl Instrum A"},{"key":"3346_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1053\/j.semnuclmed.2020.02.016","volume":"50","author":"R Klein","year":"2020","unstructured":"Klein R, Celiker-Guler E, Rotstein BH, deKemp RA. PET and SPECT tracers for myocardial perfusion imaging. Semin Nucl Med. 2020;50:208\u201318. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.016.","journal-title":"Semin Nucl Med"},{"key":"3346_CR38","unstructured":"Jalilian AR, Osso Jr J. The current status and future of theranostic Copper-64 radiopharmaceuticals.\u00a0Iran J Nucl Med. 2017;25(1): 1\u201310."},{"key":"3346_CR39","first-page":"1","volume":"24","author":"AR Jalilian","year":"2016","unstructured":"Jalilian AR. An overview on Ga-68 radiopharmaceuticals for positron emission tomography applications an overview on Ga-68 radiopharmaceuticals. Iran J Nucl Med. 2016;24:1\u201310.","journal-title":"Iran J Nucl Med"},{"key":"3346_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/instruments8010022","volume":"8","author":"K Franke","year":"2024","unstructured":"Franke K, Sch\u00f6ngart J, Mansel A. Production and processing of the radionuclide 76Br. Instruments. 2024;8:1\u20139. https:\/\/doi.org\/10.3390\/instruments8010022.","journal-title":"Instruments"},{"key":"3346_CR41","doi-asserted-by":"publisher","unstructured":"Nesterov SV. Quantification of myocardial blood flow in absolute terms u27sing 82 Rb PET imaging: results of RUBY-10\u2014a multicenter study comparing ten computer analysis programs Sergeys. Bone. 2008;23:1\u20137. https:\/\/doi.org\/10.1016\/j.jcmg.2014.08.003.Quantification.","DOI":"10.1016\/j.jcmg.2014.08.003.Quantification"},{"key":"3346_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2174\/157340611796799249","volume":"7","author":"TK Nayak","year":"2011","unstructured":"Nayak TK, Brechbiel MW. 86Y based PET radiopharmaceuticals: radiochemistry and biological applications. Med Chem (Los Angeles). 2011;7:380\u20138. https:\/\/doi.org\/10.2174\/157340611796799249.","journal-title":"Med Chem (Los Angeles)"},{"key":"3346_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14020167","volume":"14","author":"MB Mikulova","year":"2021","unstructured":"Mikulova MB, Mikus P. Advances in development of radiometal labeled amino acid-based compounds for cancer imaging and diagnostics. Pharmaceuticals. 2021;14:1\u201342. https:\/\/doi.org\/10.3390\/ph14020167.","journal-title":"Pharmaceuticals"},{"key":"3346_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020414","author":"K Kumar","year":"2021","unstructured":"Kumar K, Ghosh A. Radiochemistry, production processes, labeling methods, and immunopet imaging pharmaceuticals of iodine-124. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26020414.","journal-title":"Molecules"},{"key":"3346_CR45","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.7150\/thno.92775","volume":"14","author":"C Van Laere","year":"2024","unstructured":"Van Laere C, Koole M, Deroose CM, de Van Voor M, Baete K, Cocolios TE, Duchemin C, Ooms M, Cleeren F. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside. Theranostics. 2024;14:1720\u201343. https:\/\/doi.org\/10.7150\/thno.92775.","journal-title":"Theranostics"},{"key":"3346_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-024-00239-1","volume":"9","author":"EL Hooijman","year":"2024","unstructured":"Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, de Blois E. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9:1\u201330. https:\/\/doi.org\/10.1186\/s41181-024-00239-1.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.apradiso.2015.02.003","volume":"99","author":"SM Collins","year":"2015","unstructured":"Collins SM, Pearce AK, Ferreira KM, Fenwick AJ, Regan PH, Keightley JD. Direct measurement of the half-life of 223Ra. Appl Radiat Isot. 2015;99:46\u201353. https:\/\/doi.org\/10.1016\/j.apradiso.2015.02.003.","journal-title":"Appl Radiat Isot"},{"key":"3346_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13050599","volume":"13","author":"S Ahenkorah","year":"2021","unstructured":"Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for targeted radionuclide therapy: from atom to bedside. Pharmaceutics. 2021;13:1\u201325. https:\/\/doi.org\/10.3390\/pharmaceutics13050599.","journal-title":"Pharmaceutics"},{"key":"3346_CR49","doi-asserted-by":"publisher","unstructured":"Albertsson P, B\u00e4ck T, Bergmark K, Hallqvist A, Johansson M, Aneheim E, et al. Astatine-211 based radionuclide therapy: current clinical trial landscape. Front Med (Lausanne). 2023;9. https:\/\/doi.org\/10.3389\/fmed.2022.1076210.","DOI":"10.3389\/fmed.2022.1076210"},{"key":"3346_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.radphyschem.2022.110506","author":"M Maciak","year":"2023","unstructured":"Maciak M, Konior M, Wawszczak D, Majewska A, Brodaczewska K, Piasecki P, Narloch J, Sady M, Olszewski J, Gajewski Z, Kieda C, Dziel T, Iller E. Physical properties and biological impact of 90Y microspheres prepared by sol-gel method for liver radioembolization. Radiat Phys Chem. 2023. https:\/\/doi.org\/10.1016\/j.radphyschem.2022.110506.","journal-title":"Radiat Phys Chem"},{"key":"3346_CR51","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1021\/cr500171e","volume":"115","author":"S Banerjee","year":"2015","unstructured":"Banerjee S, Pillai MRA, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115:2934\u201374. https:\/\/doi.org\/10.1021\/cr500171e.","journal-title":"Chem Rev"},{"key":"3346_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nucmedbio.2012.09.002","volume":"40","author":"N Urbano","year":"2013","unstructured":"Urbano N, Modoni S, Schillaci O. Media fill test for validation of autologous leukocytes separation and labelling by 99mTc-HmPAO. Nucl Med Biol. 2013;40:104\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.09.002.","journal-title":"Nucl Med Biol"},{"key":"3346_CR53","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jlcr.3569","volume":"60","author":"M Boudjemeline","year":"2017","unstructured":"Boudjemeline M, Hopewell R, Rochon PL, Jolly D, Hammami I, Villeneuve S, Kostikov A. Highly efficient solid phase supported radiosynthesis of [11C]PiB using tC18 cartridge as a \u201c3-in-1\u201d production entity. J Labelled Comp Radiopharm. 2017;60:632\u20138. https:\/\/doi.org\/10.1002\/jlcr.3569.","journal-title":"J Labelled Comp Radiopharm"},{"key":"3346_CR54","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12149-014-0830-0","volume":"28","author":"K Hayashi","year":"2014","unstructured":"Hayashi K, Douhara K, Kashino G. Evaluation of the bubble point test of a 0.22-\u03bcm membrane filter used for the sterilizing filtration of PET radiopharmaceuticals. Ann Nucl Med. 2014;28:586\u201392. https:\/\/doi.org\/10.1007\/s12149-014-0830-0.","journal-title":"Ann Nucl Med"},{"key":"3346_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2016.00005","volume":"3","author":"S Chaturvedi","year":"2016","unstructured":"Chaturvedi S, Mishra AK. Small molecule radiopharmaceuticals - a review of current approaches. Front Med Lausanne. 2016;3:1\u201318. https:\/\/doi.org\/10.3389\/fmed.2016.00005.","journal-title":"Front Med Lausanne"},{"key":"3346_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bc500475e","volume":"26","author":"O Jacobson","year":"2015","unstructured":"Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26:1\u201318. https:\/\/doi.org\/10.1021\/bc500475e.","journal-title":"Bioconjug Chem"},{"key":"3346_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1979.138","volume":"40","author":"VJ Richardson","year":"1979","unstructured":"Richardson VJ, Ryman BE, Jewkes RF, Jeyasingh K, Tattersall MNH, Newlands ES, Kaye SB. Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer. 1979;40:35\u201343. https:\/\/doi.org\/10.1038\/bjc.1979.138.","journal-title":"Br J Cancer"},{"key":"3346_CR58","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/adhm.201500992","volume":"5","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Pang B, Luehmann H, Detering L, Yang X, Sultan D, Harpstrite S, Sharma V, Cutler CS, Xia Y, Liu Y. Gold nanoparticles doped with 199Au atoms and their use for targeted cancer imaging by SPECT. Adv Healthc Mater. 2016;5:928\u201335. https:\/\/doi.org\/10.1002\/adhm.201500992.","journal-title":"Adv Healthc Mater"},{"key":"3346_CR59","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1039\/c2an35863h","volume":"137","author":"C P\u00e9rez-Campa\u00f1a","year":"2012","unstructured":"P\u00e9rez-Campa\u00f1a C, G\u00f3mez-Vallejo V, Martin A, San Sebasti\u00e1n E, Moya SE, Reese T, Ziolo RF, Llop J. Tracing nanoparticles in vivo: a new general synthesis of positron emitting metal oxide nanoparticles by proton beam activation. Analyst. 2012;137:4902\u20136. https:\/\/doi.org\/10.1039\/c2an35863h.","journal-title":"Analyst"},{"key":"3346_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/pharmaceutics11080395","volume":"11","author":"Y Jabalera","year":"2019","unstructured":"Jabalera Y, Garcia-Pinel B, Ortiz R, Iglesias G, Cabeza L, Prados J, Jimenez-Lopez C, Melguizo C. Oxaliplatin\u2013biomimetic magnetic nanoparticle assemblies for colon cancer-targeted chemotherapy: an in vitro study. Pharmaceutics. 2019;11:4\u20136. https:\/\/doi.org\/10.3390\/pharmaceutics11080395.","journal-title":"Pharmaceutics"},{"key":"3346_CR61","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/nnm.14.26","volume":"9","author":"BT Cisneros","year":"2014","unstructured":"Cisneros BT, Law JJ, Matson ML, Azhdarinia A, Sevick-Muraca EM, Wilson LJ. Stable confinement of positron emission tomography and magnetic resonance agents within carbon nanotubes for bimodal imaging. Nanomedicine. 2014;9:2499\u2013509. https:\/\/doi.org\/10.2217\/nnm.14.26.","journal-title":"Nanomedicine"},{"key":"3346_CR62","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1039\/d0cs00384k","volume":"50","author":"J Pellico","year":"2021","unstructured":"Pellico J, Gawne PJ, De Rosales RTM. Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev. 2021;50:3355\u2013423. https:\/\/doi.org\/10.1039\/d0cs00384k.","journal-title":"Chem Soc Rev"},{"key":"3346_CR63","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","volume":"119","author":"TI Kostelnik","year":"2019","unstructured":"Kostelnik TI, Orvig C. Radioactive main group and rare earth metals for imaging and therapy. Chem Rev. 2019;119:902\u201356. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00294.","journal-title":"Chem Rev"},{"key":"3346_CR64","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/c3cs60304k","volume":"43","author":"EW Price","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260\u201390. https:\/\/doi.org\/10.1039\/c3cs60304k.","journal-title":"Chem Soc Rev"},{"key":"3346_CR65","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1039\/c9cs00373h","volume":"49","author":"A Steinbrueck","year":"2020","unstructured":"Steinbrueck A, Sedgwick AC, Brewster JT, Yan KC, Shang Y, Knoll DM, Vargas-Z\u00fa\u00f1iga GI, He XP, Tian H, Sessler JL. Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents. Chem Soc Rev. 2020;49:3726\u201347. https:\/\/doi.org\/10.1039\/c9cs00373h.","journal-title":"Chem Soc Rev"},{"key":"3346_CR66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.addr.2019.05.012","volume":"143","author":"F Man","year":"2019","unstructured":"Man F, Gawne PJ, de Rosales RTM. Nuclear imaging of liposomal drug delivery systems: a critical review of radiolabelling methods and applications in nanomedicine. Adv Drug Deliv Rev. 2019;143:134\u201360. https:\/\/doi.org\/10.1016\/j.addr.2019.05.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"3346_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-024-00254-2","author":"S Martin","year":"2024","unstructured":"Martin S, Wendlinger L, Litvinenko A, Faizova R, Schottelius M. Validation of a size exclusion method for concomitant purification and formulation of peptide radiopharmaceuticals. EJNMMI Radiopharm Chem. 2024. https:\/\/doi.org\/10.1186\/s41181-024-00254-2.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.675122","volume":"8","author":"I Cassells","year":"2021","unstructured":"Cassells I, Ahenkorah S, Burgoyne AR, de Van Voor M, Deroose CM, Cardinaels T, Bormans G, Ooms M, Cleeren F. Radiolabeling of human serum albumin with Terbium-161 using mild conditions and evaluation of in vivo stability. Front Med (Lausanne). 2021;8:1\u201312. https:\/\/doi.org\/10.3389\/fmed.2021.675122.","journal-title":"Front Med (Lausanne)"},{"key":"3346_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/10826076.2014.941265","volume":"38","author":"J Sherma","year":"2015","unstructured":"Sherma J, DeGrandchamp D. Review of advances in planar radiochromatography. J Liq Chromatogr Relat Technol. 2015;38:381\u20139. https:\/\/doi.org\/10.1080\/10826076.2014.941265.","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"3346_CR70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpba.2015.04.009","volume":"111","author":"D Ory","year":"2015","unstructured":"Ory D, den Van Brande J, de Groot T, Serdons K, Bex M, Declercq L, Cleeren F, Ooms M, Van Laere K, Verbruggen A, Bormans G. Retention of [18F]fluoride on reversed phase HPLC columns. J Pharm Biomed Anal. 2015;111:209\u201314. https:\/\/doi.org\/10.1016\/j.jpba.2015.04.009.","journal-title":"J Pharm Biomed Anal"},{"key":"3346_CR71","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.apradiso.2009.02.077","volume":"67","author":"D Franck","year":"2009","unstructured":"Franck D, Nann H, Davi P, Schubiger PA, Ametamey SM. Faster analysis of radiopharmaceuticals using ultra performance liquid chromatography (UPLC\u00ae) in combination with low volume radio flow cell. Appl Radiat Isot. 2009;67:1068\u201370. https:\/\/doi.org\/10.1016\/j.apradiso.2009.02.077.","journal-title":"Appl Radiat Isot"},{"key":"3346_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14653240802075476","volume":"10","author":"AP Gee","year":"2008","unstructured":"Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R. A multicenter comparison study between the Endosafe\u00ae PTS\u2122 rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. Cytotherapy. 2008;10:427\u201335. https:\/\/doi.org\/10.1080\/14653240802075476.","journal-title":"Cytotherapy"},{"key":"3346_CR73","doi-asserted-by":"publisher","unstructured":"Varghese TP, John A, Mathew J. Revolutionizing cancer treatment: the role of radiopharmaceuticals in modern cancer therapy. Precis Radiat Oncol. 2024;145\u2013152. https:\/\/doi.org\/10.1002\/pro6.1239.","DOI":"10.1002\/pro6.1239"},{"key":"3346_CR74","doi-asserted-by":"publisher","unstructured":"Yang K, Li J, Cheng Y, Bai C. Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades. Endocr Connect. 2023;12. https:\/\/doi.org\/10.1530\/EC-22-0441.","DOI":"10.1530\/EC-22-0441"},{"key":"3346_CR75","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/10600280231155441","volume":"57","author":"MJ Hadfield","year":"2023","unstructured":"Hadfield MJ, Lyall V, Holle LM, Dennison M. Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists. Ann Pharmacother. 2023;57:1302\u201311. https:\/\/doi.org\/10.1177\/10600280231155441.","journal-title":"Ann Pharmacother"},{"key":"3346_CR76","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2967\/jnumed.122.265199","volume":"64","author":"AK Buck","year":"2023","unstructured":"Buck AK, Serfling SE, Kraus S, Samnick S, Dreher N, Higuchi T, Rasche L, Einsele H, Werner RA. Theranostics in hematooncology. J Nucl Med. 2023;64:1009\u201316. https:\/\/doi.org\/10.2967\/jnumed.122.265199.","journal-title":"J Nucl Med"},{"key":"3346_CR77","first-page":"4107","volume":"29","author":"G Ting","year":"2009","unstructured":"Ting G, Chang CH, Wang HE. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res. 2009;29:4107\u201318.","journal-title":"Anticancer Res"},{"key":"3346_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/inorganics8040028","volume":"8","author":"I Fern\u00e1ndez-Barahona","year":"2020","unstructured":"Fern\u00e1ndez-Barahona I, Mu\u00f1oz-Hernando M, Ruiz-Cabello J, Herranz F, Pellico J. Iron oxide nanoparticles: an alternative for positive contrast in magnetic resonance imaging. Inorganics (Basel). 2020;8:1\u201322. https:\/\/doi.org\/10.3390\/inorganics8040028.","journal-title":"Inorganics (Basel)"},{"key":"3346_CR79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/ntno.64141","volume":"6","author":"H Duan","year":"2022","unstructured":"Duan H, Iagaru A, Aparici CM. Radiotheranostics \u2013 precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022;6:103\u201317. https:\/\/doi.org\/10.7150\/ntno.64141.","journal-title":"Nanotheranostics"},{"key":"3346_CR80","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.drudis.2022.03.001","volume":"27","author":"D Yilmaz","year":"2022","unstructured":"Yilmaz D, Sharp PS, Main MJ, Simpson PB. Advanced molecular imaging for the characterisation of complex medicines. Drug Discov Today. 2022;27:1716\u201323. https:\/\/doi.org\/10.1016\/j.drudis.2022.03.001.","journal-title":"Drug Discov Today"},{"key":"3346_CR81","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.neubiorev.2013.03.022","volume":"37","author":"TR Insel","year":"2013","unstructured":"Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ. Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev. 2013;37:2438\u201344. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.03.022.","journal-title":"Neurosci Biobehav Rev"},{"key":"3346_CR82","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1021\/nn900761s","volume":"3","author":"L Relaxivity","year":"2009","unstructured":"Relaxivity L, Particle O, Park JY, Baek MJ, Choi ES, Woo S, Kim JH, Kim TJ, Jung JC, Chae S, Chang Y, Lee GH. Oxide Nanoparticles as Advanced T 1. ACS Nano. 2009;3:3663\u20139.","journal-title":"ACS Nano"},{"key":"3346_CR83","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12951-024-02859-w","volume":"22","author":"X Meng","year":"2024","unstructured":"Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review. J Nanobiotechnology. 2024;22:587. https:\/\/doi.org\/10.1186\/s12951-024-02859-w.","journal-title":"J Nanobiotechnology"},{"key":"3346_CR84","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1039\/d0cs00384k","volume":"50","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Radiolabeling nanomaterials for medical imaging and therapy. Chem Soc Rev. 2021;50:1273\u2013340. https:\/\/doi.org\/10.1039\/d0cs00384k.","journal-title":"Chem Soc Rev"},{"key":"3346_CR85","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.2147\/IJN.S413141","volume":"18","author":"NN Yue","year":"2023","unstructured":"Yue NN, Xu HM, Xu J, Zhu MZ, Zhang Y, Tian CM, Nie YQ, Yao J, Liang YJ, Li DF, Wang LS. Application of nanoparticles in the diagnosis of gastrointestinal diseases: a complete future perspective. Int J Nanomedicine. 2023;18:4143\u201370. https:\/\/doi.org\/10.2147\/IJN.S413141.","journal-title":"Int J Nanomedicine"},{"key":"3346_CR86","doi-asserted-by":"publisher","unstructured":"Crestoni ME. Radiopharmaceuticals for diagnosis and therapy. Elsevier Inc.; 2018. https:\/\/doi.org\/10.1016\/b978-0-12-409547-2.14205-2.","DOI":"10.1016\/b978-0-12-409547-2.14205-2"},{"key":"3346_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13030039","volume":"13","author":"I Velikyan","year":"2020","unstructured":"Velikyan I. (Radio)theranostic patient management in oncology exemplified by neuroendocrine neoplasms, prostate cancer, and breast cancer. Pharmaceuticals. 2020;13:1\u201325. https:\/\/doi.org\/10.3390\/ph13030039.","journal-title":"Pharmaceuticals"},{"key":"3346_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102594","volume":"64","author":"P Shende","year":"2021","unstructured":"Shende P, Gandhi S. Current strategies of radiopharmaceuticals in theranostic applications. J Drug Deliv Sci Technol. 2021;64: 102594. https:\/\/doi.org\/10.1016\/j.jddst.2021.102594.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3346_CR89","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s13139-015-0323-7","volume":"49","author":"A Mirzaei","year":"2015","unstructured":"Mirzaei A, Jalilian AR, Aghanejad A, Mazidi M, Yousefnia H, Shabani G, Ardaneh K, Geramifar P, Beiki D. Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent. Nucl Med Mol Imaging. 2015;49:208\u201316. https:\/\/doi.org\/10.1007\/s13139-015-0323-7.","journal-title":"Nucl Med Mol Imaging"},{"key":"3346_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1524\/ract.2011.1891","volume":"100","author":"S Adak","year":"2012","unstructured":"Adak S, Bhalla R, Vijaya Raj KK, Mandal S, Pickett R, Luthra SK. Radiotracers for SPECT imaging: current scenario and future prospects. Radiochim Acta. 2012;100:95\u2013107. https:\/\/doi.org\/10.1524\/ract.2011.1891.","journal-title":"Radiochim Acta"},{"key":"3346_CR91","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2217\/nnm-2017-0110","volume":"12","author":"D Vecchione","year":"2017","unstructured":"Vecchione D, Aiello M, Cavaliere C, Nicolai E, Netti PA, Torino E. Hybrid core shell nanoparticles entrapping Gd-DTPA and 18F-FDG for simultaneous PET\/MRI acquisitions. Nanomedicine. 2017;12:2223\u201331. https:\/\/doi.org\/10.2217\/nnm-2017-0110.","journal-title":"Nanomedicine"},{"key":"3346_CR92","doi-asserted-by":"publisher","unstructured":"Aghanejad A, Omidi Y. Radiolabeled theranostics. Elsevier Inc.; 2019. https:\/\/doi.org\/10.1016\/B978-0-12-814134-2.00025-5.","DOI":"10.1016\/B978-0-12-814134-2.00025-5"},{"key":"3346_CR93","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2310\/7290.2012.00038","volume":"12","author":"J Yuan","year":"2013","unstructured":"Yuan J, Zhang H, Kaur H, Oupicky D, Peng F. Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA- 64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron emission tomography. Mol Imaging. 2013;12:203\u201312. https:\/\/doi.org\/10.2310\/7290.2012.00038.","journal-title":"Mol Imaging"},{"key":"3346_CR94","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.bjc.6604561","volume":"99","author":"T Lammers","year":"2008","unstructured":"Lammers T, Subr V, Peschke P, K\u00fchnlein R, Hennink WE, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber PE, Storm G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer. 2008;99:900\u201310. https:\/\/doi.org\/10.1038\/sj.bjc.6604561.","journal-title":"Br J Cancer"},{"key":"3346_CR95","doi-asserted-by":"publisher","first-page":"10906","DOI":"10.1039\/c7nr03306k","volume":"9","author":"E Koziolov\u00e1","year":"2017","unstructured":"Koziolov\u00e1 E, Goel S, Chytil P, Janou\u0161kov\u00e1 O, Barnhart TE, Cai W, Etrych T. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging. Nanoscale. 2017;9:10906\u201318. https:\/\/doi.org\/10.1039\/c7nr03306k.","journal-title":"Nanoscale"},{"key":"3346_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12645-023-00165-y","volume":"14","author":"M Goel","year":"2023","unstructured":"Goel M, Mackeyev Y, Krishnan S. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts. Cancer Nanotechnol. 2023;14:1\u201336. https:\/\/doi.org\/10.1186\/s12645-023-00165-y.","journal-title":"Cancer Nanotechnol"},{"key":"3346_CR97","doi-asserted-by":"publisher","first-page":"169","DOI":"10.15171\/bi.2016.23","volume":"6","author":"S Same","year":"2016","unstructured":"Same S, Aghanejad A, Nakhjavani SA, Barar J, Omidi Y. Radiolabeled theranostics: magnetic and gold nanoparticles. BioImpacts. 2016;6:169\u201381. https:\/\/doi.org\/10.15171\/bi.2016.23.","journal-title":"BioImpacts"},{"key":"3346_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/am.2016.80","volume":"8","author":"SB Lee","year":"2016","unstructured":"Lee SB, Ahn SB, Lee SW, Jeong SY, Ghilsuk Y, Ahn BC, Kim EM, Jeong HJ, Lee J, Lim DK, Jeon YH. Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and cerenkov luminescence. NPG Asia Mater. 2016;8:1\u201310. https:\/\/doi.org\/10.1038\/am.2016.80.","journal-title":"NPG Asia Mater"},{"key":"3346_CR99","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1016\/j.bmcl.2013.04.002","volume":"23","author":"HW Kao","year":"2013","unstructured":"Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin MH, Wang HE. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett. 2013;23:3180\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2013.04.002.","journal-title":"Bioorg Med Chem Lett"},{"key":"3346_CR100","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11307-013-0635-x","volume":"15","author":"M Tian","year":"2013","unstructured":"Tian M, Lu W, Zhang R, Xiong C, Ensor J, Nazario J, Jackson J, Shaw C, Dixon KA, Miller J, Wright K, Li C, Gupta S. Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET\/CT study in a rabbit VX2 liver cancer model. Mol Imaging Biol. 2013;15:614\u201324. https:\/\/doi.org\/10.1007\/s11307-013-0635-x.","journal-title":"Mol Imaging Biol"},{"key":"3346_CR101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.08.048","volume":"108","author":"X Li","year":"2016","unstructured":"Li X, Wang C, Tan H, Cheng L, Liu G, Yang Y, Zhao Y, Zhang Y, Li Y, Zhang C, Xiu Y, Cheng D, Shi H. Gold nanoparticles-based SPECT\/CT imaging probe targeting for vulnerable atherosclerosis plaques. Biomaterials. 2016;108:71\u201380. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.08.048.","journal-title":"Biomaterials"},{"key":"3346_CR102","doi-asserted-by":"publisher","first-page":"28195","DOI":"10.1021\/acsami.7b07589","volume":"9","author":"Y Yang","year":"2017","unstructured":"Yang Y, Liu Y, Cheng C, Shi H, Yang H, Yuan H, Ni C. Rational design of GO-modified Fe3O4\/SiO2 nanoparticles with combined Rhenium-188 and gambogic acid for magnetic target therapy. ACS Appl Mater Interfaces. 2017;9:28195\u2013208. https:\/\/doi.org\/10.1021\/acsami.7b07589.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3346_CR103","doi-asserted-by":"publisher","first-page":"19573","DOI":"10.1039\/c6nr07062k","volume":"8","author":"H Gao","year":"2016","unstructured":"Gao H, Liu X, Tang W, Niu D, Zhou B, Zhang H, Liu W, Gu B, Zhou X, Zheng Y, Sun Y, Jia X, Zhou L. 99mTc-conjugated manganese-based mesoporous silica nanoparticles for SPECT, pH-responsive MRI and anti-cancer drug delivery. Nanoscale. 2016;8:19573\u201380. https:\/\/doi.org\/10.1039\/c6nr07062k.","journal-title":"Nanoscale"},{"key":"3346_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071086","author":"H Yamaguchi","year":"2016","unstructured":"Yamaguchi H, Tsuchimochi M, Hayama K, Kawase T, Tsubokawa N. Dual-labeled near-infrared\/99mTc imaging probes using PAMAM-coated silica nanoparticles for the imaging of HER2-expressing cancer cells. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17071086.","journal-title":"Int J Mol Sci"},{"key":"3346_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0477-0","volume":"10","author":"JW Lee","year":"2017","unstructured":"Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, Koo HH, Cho EJ, Lee SK, Lim DH. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10:1\u201311. https:\/\/doi.org\/10.1186\/s13045-017-0477-0.","journal-title":"J Hematol Oncol"},{"key":"3346_CR106","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1007\/s00259-018-4083-3","volume":"45","author":"S Dizdarevic","year":"2018","unstructured":"Dizdarevic S, Jessop M, Begley P, Main S, Robinson A. 223Ra-dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging. 2018;45:2264\u201373. https:\/\/doi.org\/10.1007\/s00259-018-4083-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3346_CR107","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2174\/138161209787582020","volume":"15","author":"J Turner","year":"2009","unstructured":"Turner J. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Curr Pharm Des. 2009;15:966\u201382. https:\/\/doi.org\/10.2174\/138161209787582020.","journal-title":"Curr Pharm Des"},{"key":"3346_CR108","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nrd1413","volume":"3","author":"DE Milenic","year":"2004","unstructured":"Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488\u201398. https:\/\/doi.org\/10.1038\/nrd1413.","journal-title":"Nat Rev Drug Discov"},{"key":"3346_CR109","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","volume":"61","author":"TG Chan","year":"2020","unstructured":"Chan TG, O\u2019Neill E, Habjan C, Cornelissen B. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020;61:1544\u201352. https:\/\/doi.org\/10.2967\/jnumed.120.248062.","journal-title":"J Nucl Med"},{"key":"3346_CR110","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.119.236091","volume":"61","author":"ES Delpassand","year":"2020","unstructured":"Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, N\u00fa\u00f1ez R. 64Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-Positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. J Nucl Med. 2020;61:890\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.236091.","journal-title":"J Nucl Med"},{"key":"3346_CR111","doi-asserted-by":"crossref","unstructured":"Avril N, Ros\u00e9 CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495\u2013502.","DOI":"10.1200\/JCO.2000.18.20.3495"},{"key":"3346_CR112","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, Salloway S, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonomovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Southekal S, Mintun MA. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829\u201339. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0528.","journal-title":"JAMA Neurol"},{"key":"3346_CR113","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ejso.2009.01.007","volume":"35","author":"MU Khan","year":"2009","unstructured":"Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A. Clinical indications for gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009;35:561\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2009.01.007.","journal-title":"Eur J Surg Oncol"},{"key":"3346_CR114","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874471008666150313114644","volume":"9","author":"T Das","year":"2015","unstructured":"Das T, Banerjee S. Theranostic applications of lutetium-177 in radionuclide therapy. Curr Radiopharm. 2015;9:94\u2013101. https:\/\/doi.org\/10.2174\/1874471008666150313114644.","journal-title":"Curr Radiopharm"},{"key":"3346_CR115","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s12350-015-0073-z","volume":"22","author":"NR Aggarwal","year":"2015","unstructured":"Aggarwal NR, Drozdova A, Wells Askew J, Kemp BJ, Chareonthaitawee P. Feasibility and diagnostic accuracy of exercise treadmill nitrogen-13 ammonia PET myocardial perfusion imaging of obese patients. J Nucl Cardiol. 2015;22:1273\u201380. https:\/\/doi.org\/10.1007\/s12350-015-0073-z.","journal-title":"J Nucl Cardiol"},{"key":"3346_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2015.00065","volume":"2","author":"JF Chatal","year":"2015","unstructured":"Chatal JF, Rouzet F, Haddad F, Bourdeau C, Mathieu C, Le Guludec D. Story of rubidium-82 and advantages for myocardial perfusion PET imaging. Front Med (Lausanne). 2015;2:1\u20137. https:\/\/doi.org\/10.3389\/fmed.2015.00065.","journal-title":"Front Med (Lausanne)"},{"key":"3346_CR117","first-page":"1101","volume":"37","author":"AB Packard","year":"1996","unstructured":"Packard AB, Roach PJ, Davis RT, Carmant L, Davis R, Riviello J, Holmes G, Barnes PD, O\u2019Tuama LA, Bjornson B, Treves ST. Ictal and interictal technetium-99m-bicisate brain SPECT in children with refractory epilepsy. J Nucl Med. 1996;37:1101\u20136.","journal-title":"J Nucl Med"},{"key":"3346_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2152\/jmi.56.136","volume":"56","author":"H Otsuka","year":"2009","unstructured":"Otsuka H, Terazawa K, Morita N, Otomi Y, Takao S, Iwamoto S, Osaki K, Harada M, Nishitani H. Thallium-201 chloride scintigraphy in soft tissue tumors. J Med Invest. 2009;56:136\u201341. https:\/\/doi.org\/10.2152\/jmi.56.136.","journal-title":"J Med Invest"},{"key":"3346_CR119","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, D\u2019Amore F, Diaz MG, Petrini M, Sebban C, Zinzani PL, Van Oers MHJ, Van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156\u201364. https:\/\/doi.org\/10.1200\/JCO.2008.17.2015.","journal-title":"J Clin Oncol"},{"key":"3346_CR120","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970\u201388. https:\/\/doi.org\/10.1007\/s00259-018-3945-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3346_CR121","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.semnuclmed.2024.02.002","volume":"54","author":"G Santo","year":"2024","unstructured":"Santo G, Di Santo G, Virgolini I. Peptide receptor radionuclide therapy of neuroendocrine tumors: agonist, antagonist and alternatives. Semin Nucl Med. 2024;54:557\u201369. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.002.","journal-title":"Semin Nucl Med"},{"key":"3346_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030334","author":"PMD Gape","year":"2024","unstructured":"Gape PMD, Schultz MK, Stasiuk GJ, Terry SYA. Towards effective targeted alpha therapy for neuroendocrine tumours: a review. Pharmaceuticals. 2024. https:\/\/doi.org\/10.3390\/ph17030334.","journal-title":"Pharmaceuticals"},{"key":"3346_CR123","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garc\u00eda-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herr WW, Ferone D. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, pha. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"3346_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2024.1373606","volume":"14","author":"Y Yan","year":"2024","unstructured":"Yan Y, Zhuo H, Li T, Zhang J, Tan M, Chen Y. Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review. Front Oncol. 2024;14:1\u201312. https:\/\/doi.org\/10.3389\/fonc.2024.1373606.","journal-title":"Front Oncol"},{"key":"3346_CR125","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA, Mendiratta P, Barata PC, Jia AY, Spratt DE, Brown JR. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther. 2023;23:731\u201344. https:\/\/doi.org\/10.1080\/14737140.2023.2213892.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3346_CR126","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1874471008666150313114005","volume":"9","author":"S Vallabhajosula","year":"2015","unstructured":"Vallabhajosula S, Nikolopoulou A, Jhanwar Y, Kaur G, Tagawa S, Nanus D, Bander N, Goldsmith S. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2015;9:44\u201353. https:\/\/doi.org\/10.2174\/1874471008666150313114005.","journal-title":"Curr Radiopharm"},{"key":"3346_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2025.1549676","volume":"12","author":"N Lepareur","year":"2025","unstructured":"Lepareur N. An overview of current phase 3 radiopharmaceutical therapy clinical trials. Front Med (Lausanne). 2025;12:1\u20136. https:\/\/doi.org\/10.3389\/fmed.2025.1549676.","journal-title":"Front Med (Lausanne)"},{"key":"3346_CR128","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.semnuclmed.2024.05.006","volume":"54","author":"S Mahajan","year":"2024","unstructured":"Mahajan S, Gavane S, Pandit-Taskar N. Targeted radiopharmaceutical therapy for bone metastases. Semin Nucl Med. 2024;54:497\u2013512. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.05.006.","journal-title":"Semin Nucl Med"},{"key":"3346_CR129","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ando.2023.07.138","volume":"84","author":"L Lamartina","year":"2023","unstructured":"Lamartina L, Leboulleux S, Bournaud C, Chougnet C, Zerdoud S, Do Cao C, Catargi B, Dygai I, Kelly A, Barge ML, Vera P, Rusu D, Schneegans O, Roux J, Klein M, Benisvy D, Eberle MC, Bidault S, Nascimento C, Bastie D, Giraudet AL, Bardet S, Le Moullec N, Roudaut N, Drui D, Godbert Y, Zalzali M, Drutel A, Morel O, Velayoudom FL, Al Ghuzlan A, Schlumberger M, Buffet C, Borget I. Estimabl2 trial: thyroidectomy without radioiodine in patients with low-risk thyroid cancer, 5 years of follow-up. Ann Endocrinol (Paris). 2023;84:557\u20138. https:\/\/doi.org\/10.1016\/j.ando.2023.07.138.","journal-title":"Ann Endocrinol (Paris)"},{"key":"3346_CR130","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1435302","author":"C Bouvry","year":"2018","unstructured":"Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial radioembolization (TARE) agents beyond 90Y-microspheres. Biomed Res Int. 2018. https:\/\/doi.org\/10.1155\/2018\/1435302.","journal-title":"Biomed Res Int"},{"key":"3346_CR131","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155-1163.e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029.","journal-title":"Gastroenterology"},{"key":"3346_CR132","doi-asserted-by":"crossref","unstructured":"World J Gastroenterol 2022;28(48): 6791-6961.","DOI":"10.3748\/wjg.v28.i48.6791"},{"key":"3346_CR133","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjh.12695","volume":"164","author":"A Ibatici","year":"2014","unstructured":"Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM. Safety and efficacy of 90Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol. 2014;164:710\u20136. https:\/\/doi.org\/10.1111\/bjh.12695.","journal-title":"Br J Haematol"},{"key":"3346_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0386-4","author":"J Kurth","year":"2018","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Stegger L, Sch\u00e4fers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018. https:\/\/doi.org\/10.1186\/s13550-018-0386-4.","journal-title":"EJNMMI Res"},{"key":"3346_CR135","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted a-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"key":"3346_CR136","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/RLU.0000000000000290","volume":"38","author":"H Jadvar","year":"2013","unstructured":"Jadvar H, Quinn DI. Targeted \u03b1-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013;38:966\u201371. https:\/\/doi.org\/10.1097\/RLU.0000000000000290.","journal-title":"Clin Nucl Med"},{"key":"3346_CR137","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331. https:\/\/doi.org\/10.2967\/jnumed.117.191395.","journal-title":"J Nucl Med"},{"key":"3346_CR138","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40336-021-00437-w","volume":"9","author":"NM Gillings","year":"2021","unstructured":"Gillings NM, Elsinga PH. Spotlight on: guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals published in EJNMMI Radiopharmacy and Chemistry (2021)6:8. Clin Transl Imaging. 2021;9:281\u20132. https:\/\/doi.org\/10.1007\/s40336-021-00437-w.","journal-title":"Clin Transl Imaging"},{"key":"3346_CR139","doi-asserted-by":"publisher","unstructured":"Bhatt NB, Pandya DN, Wadas TJ. Recent advances in zirconium-89 chelator development. Molecules. 2018;23. https:\/\/doi.org\/10.3390\/molecules23030638.","DOI":"10.3390\/molecules23030638"},{"key":"3346_CR140","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/A:1023964712999","volume":"256","author":"A Bogni","year":"2003","unstructured":"Bogni A, Bombardieri E, Iwata R, Cadini L, Pascali C. Stability of l-[S-methyl-11C]methionine solutions. J Radioanal Nucl Chem. 2003;256:199\u2013203. https:\/\/doi.org\/10.1023\/A:1023964712999.","journal-title":"J Radioanal Nucl Chem"},{"key":"3346_CR141","first-page":"700","volume":"46","author":"OR Pozzi","year":"2005","unstructured":"Pozzi OR, Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At \u03b1-particles. J Nucl Med. 2005;46:700\u20136.","journal-title":"J Nucl Med"},{"key":"3346_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041884","author":"A Larenkov","year":"2023","unstructured":"Larenkov A, Mitrofanov I, Pavlenko E, Rakhimov M. Radiolysis-associated decrease in radiochemical purity of 177Lu-radiopharmaceuticals and comparison of the effectiveness of selected quenchers against this process. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28041884.","journal-title":"Molecules"},{"key":"3346_CR143","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","volume":"49","author":"A Dash","year":"2015","unstructured":"Dash A, Pillai MRA, Knapp FF. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49:85\u2013107. https:\/\/doi.org\/10.1007\/s13139-014-0315-z.","journal-title":"Nucl Med Mol Imaging"},{"key":"3346_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/pr10061215","author":"T Higashi","year":"2022","unstructured":"Higashi T, Nagatsu K, Tsuji AB, Zhang MR. Research and development for cyclotron production of225Ac from226Ra\u2014the challenges in a country lacking natural resources for medical applications. Processes. 2022. https:\/\/doi.org\/10.3390\/pr10061215.","journal-title":"Processes"},{"key":"3346_CR145","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.tibtech.2013.04.007","volume":"31","author":"GC Krijger","year":"2013","unstructured":"Krijger GC, Ponsard B, Harfensteller M, Wolterbeek HT, Nijsen JWF. The necessity of nuclear reactors for targeted radionuclide therapies. Trends Biotechnol. 2013;31:390\u20136. https:\/\/doi.org\/10.1016\/j.tibtech.2013.04.007.","journal-title":"Trends Biotechnol"},{"key":"3346_CR146","doi-asserted-by":"publisher","unstructured":"Guidoccio F, Mazzarri S, Orsini F, Erba PA, Mariani G. Novel radiopharmaceuticals for therapy. 2017. https:\/\/doi.org\/10.1007\/978-3-319-26236-9_36.","DOI":"10.1007\/978-3-319-26236-9_36"},{"key":"3346_CR147","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.mnm.0000169377.07518.f9","volume":"26","author":"FJ De vos","year":"2005","unstructured":"De vos FJ, De Decker M, Dierckx RA. The good laboratory practice and good clinical practice requirements for the production of radiopharmaceuticals in clinical research. Nucl Med Commun. 2005;26:575\u20139. https:\/\/doi.org\/10.1097\/01.mnm.0000169377.07518.f9.","journal-title":"Nucl Med Commun"},{"key":"3346_CR148","doi-asserted-by":"crossref","unstructured":"Jo JJ, Lee SH, Ki BH, Ryu HJ, Kim TH, Kim GS, Lee SK, Kim DW, Kim KB, Kim S, Choi SH. Evaluation of radioactivity in therapeutic radiopharmaceutical waste.  Prog Med Phys. 2024;35:163\u2013171.","DOI":"10.14316\/pmp.2024.35.4.163"},{"key":"3346_CR149","doi-asserted-by":"publisher","unstructured":"Prevot S, Dyga\u00ef-Cochet I, Riedinger JM, Vrigneaud JM, Quermonne M, Gallet M, Cochet A. Dealing with dry waste disposal issues associated with 177mLu impurities: a long-term challenge for nuclear medicine departments. EJNMMI Phys. 2023;10. https:\/\/doi.org\/10.1186\/s40658-023-00524-z.","DOI":"10.1186\/s40658-023-00524-z"},{"key":"3346_CR150","doi-asserted-by":"publisher","unstructured":"Zoberi JE, Garcia-Ramirez J, Luechtefeld D, Maughan NM, Amurao M, Oyama R, Baumann BC, Gay HA, Michalski JM. Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: a case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy. J Appl Clin Med Phys. 2023;24. https:\/\/doi.org\/10.1002\/acm2.13899.","DOI":"10.1002\/acm2.13899"},{"key":"3346_CR151","doi-asserted-by":"publisher","first-page":"279","DOI":"10.22270\/jddt.v8i6-s.2135","volume":"8","author":"S Sharma","year":"2018","unstructured":"Sharma S, Baldi A, Singh RK, Sharma RK. Drafting of comprehensive harmonized regulatory guideline for storage and disposal of radiopharmaceuticals. J Drug Deliv Ther. 2018;8:279\u201386. https:\/\/doi.org\/10.22270\/jddt.v8i6-s.2135.","journal-title":"J Drug Deliv Ther"},{"key":"3346_CR152","first-page":"91","volume":"45","author":"A Ta\u015f","year":"2020","unstructured":"Ta\u015f A, \u00d6zer AY. Waste disposal and management in radiopharmaceuticals. Fabad J Pharm Sci. 2020;45:91\u2013103.","journal-title":"Fabad J Pharm Sci"},{"key":"3346_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051378","author":"CN Funeh","year":"2023","unstructured":"Funeh CN, Bridoux J, Ertveldt T, De Groof TWM, Chigoho DM, Asiabi P, Covens P, D\u2019Huyvetter M, Devoogdt N. Optimizing the safety and efficacy of bio-radiopharmaceuticals for cancer therapy. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15051378.","journal-title":"Pharmaceutics"},{"key":"3346_CR154","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.121.263301","volume":"63","author":"M Perera","year":"2022","unstructured":"Perera M, Morris MJ. From concept to regulatory drug approval: lessons for theranostics. J Nucl Med. 2022;63:1793\u2013801. https:\/\/doi.org\/10.2967\/jnumed.121.263301.","journal-title":"J Nucl Med"},{"key":"3346_CR155","first-page":"131","volume":"32","author":"C Decristoforo","year":"2007","unstructured":"Decristoforo C. Challenges in the small-scale preparation of radiopharmaceuticals - a European perspective. Fabad J Pharm Sci. 2007;32:131\u20138.","journal-title":"Fabad J Pharm Sci"},{"key":"3346_CR156","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2967\/jnumed.118.209460","volume":"60","author":"SW Schwarz","year":"2019","unstructured":"Schwarz SW, Decristoforo C, Goodbody AE, Singhal N, Saliba S, Ruddock PS, Zukotynski K, Ross AA. Harmonization of U.S., European Union, and Canadian first-in-human regulatory requirements for radiopharmaceuticals: is this possible? J Nucl Med. 2019;60:158\u201366. https:\/\/doi.org\/10.2967\/jnumed.118.209460.","journal-title":"J Nucl Med"},{"key":"3346_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-022-00168-x","author":"A Korde","year":"2022","unstructured":"Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, Koole M, Herth MM, Bardi\u00e8s M, Martins AF, Paulo A, Lyashchenko SK, Todde S, Nag S, Lamprou E, Abrunhosa A, Giammarile F, Decristoforo C. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2022. https:\/\/doi.org\/10.1186\/s41181-022-00168-x.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR158","doi-asserted-by":"publisher","DOI":"10.1007\/s12038-021-00147-5","author":"D Kaushik","year":"2021","unstructured":"Kaushik D, Jangra P, Verma R, Purohit D, Pandey P, Sharma S, Sharma RK. Radiopharmaceuticals: an insight into the latest advances in medical uses and regulatory perspectives. J Biosci. 2021. https:\/\/doi.org\/10.1007\/s12038-021-00147-5.","journal-title":"J Biosci"},{"key":"3346_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00230-2","author":"A Korde","year":"2024","unstructured":"Korde A, Patt M, Selivanova SV, Scott AM, Hesselmann R, Kiss O, Ramamoorthy N, Todde S, Rubow SM, Gwaza L, Lyashchenko S, Andersson J, Hockley B, Kaslival R, Decristoforo C. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI Radiopharm Chem. 2024. https:\/\/doi.org\/10.1186\/s41181-023-00230-2.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR160","doi-asserted-by":"publisher","first-page":"275","DOI":"10.26479\/2018.0403.25","volume":"4","author":"S Sharma","year":"2018","unstructured":"Sharma S, Baldi A, Singh R, Sharma RK. Regulatory framework of radiopharmaceuticals\u202f: current status regulatory framework of radiopharmaceuticals\u202f: Res J Life Sci Bioinform Pharm Chem Sci. 2018;4:275\u201390. https:\/\/doi.org\/10.26479\/2018.0403.25.","journal-title":"Res J Life Sci Bioinform Pharm Chem Sci"},{"key":"3346_CR161","doi-asserted-by":"publisher","first-page":"47","DOI":"10.18520\/cs\/v116\/i1\/47-55","volume":"116","author":"S Sharma","year":"2019","unstructured":"Sharma S, Jain S, Baldi A, Singh RK, Sharma RK. Intricacies in the approval of radiopharmaceuticals - regulatory perspectives and the way forward. Curr Sci. 2019;116:47\u201355. https:\/\/doi.org\/10.18520\/cs\/v116\/i1\/47-55.","journal-title":"Curr Sci"},{"key":"3346_CR162","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41181-019-0059-2","volume":"4","author":"SW Schwarz","year":"2019","unstructured":"Schwarz SW, Decristoforo C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharm Chem. 2019;4:2\u20136. https:\/\/doi.org\/10.1186\/s41181-019-0059-2.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3346_CR163","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1053\/j.semnuclmed.2010.05.002","volume":"40","author":"RS Harapanhalli","year":"2010","unstructured":"Harapanhalli RS. Food and drug administration requirements for testing and approval of new radiopharmaceuticals. Semin Nucl Med. 2010;40:364\u201384. https:\/\/doi.org\/10.1053\/j.semnuclmed.2010.05.002.","journal-title":"Semin Nucl Med"},{"key":"3346_CR164","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.02.007","author":"J Cairns","year":"2025","unstructured":"Cairns J, Frood R, Patel C, Scarsbrook A. The role of AI in lymphoma: an update. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.007.","journal-title":"Semin Nucl Med"},{"key":"3346_CR165","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1515\/oncologie-2024-0543","volume":"27","author":"BD Ayalew","year":"2025","unstructured":"Ayalew BD, Abdullah SM, Khan ZG, Alemayehu MG, Teferi BT, Aboye EM, Woldeyohannes BL, Sime YT, Tewodros MI. Hundisa, Role of emerging theranostic technologies in precision oncology: revolutionizing cancer diagnosis and treatment. Oncologie. 2025;27:229\u201338. https:\/\/doi.org\/10.1515\/oncologie-2024-0543.","journal-title":"Oncologie"},{"key":"3346_CR166","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2967\/jnumed.120.254110","volume":"62","author":"R Vali","year":"2021","unstructured":"Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. SNMMI procedure standard\/EANM practice guideline on pediatric 18F-FDG PET\/CT for oncology 1.0. J Nucl Med. 2021;62:99\u2013110. https:\/\/doi.org\/10.2967\/jnumed.120.254110.","journal-title":"J Nucl Med"},{"key":"3346_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.1062592","volume":"12","author":"A Rahmim","year":"2022","unstructured":"Rahmim A, Brosch-Lenz J, Fele-Paranj A, Yousefirizi F, Soltani M, Uribe C, Saboury B. Theranostic digital twins for personalized radiopharmaceutical therapies: reimagining theranostics via computational nuclear oncology. Front Oncol. 2022;12:1\u20137. https:\/\/doi.org\/10.3389\/fonc.2022.1062592.","journal-title":"Front Oncol"},{"key":"3346_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/life13081647","author":"M Balma","year":"2023","unstructured":"Balma M, Laudicella R, Gallio E, Gusella S, Lorenzon L, Peano S, Costa RP, Rampado O, Farsad M, Evangelista L, Deandreis D, Papaleo A, Liberini V. Applications of artificial intelligence and radiomics in molecular hybrid imaging and theragnostics for neuro-endocrine neoplasms (NENs). Life. 2023. https:\/\/doi.org\/10.3390\/life13081647.","journal-title":"Life"},{"key":"3346_CR169","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1007\/s00259-022-05891-w","volume":"49","author":"D Visvikis","year":"2022","unstructured":"Visvikis D, Lambin P, Mauridsen KB, Hustinx R, Lassmann M, Rischpler C, Shi K, Pruim J. Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. Eur J Nucl Med Mol Imaging. 2022;49:4452\u201363. https:\/\/doi.org\/10.1007\/s00259-022-05891-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3346_CR170","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-025-02031-w","author":"MX Zhang","year":"2025","unstructured":"Zhang MX, Liu PF, Zhang MD, Su PG, Shang HS, Zhu JT, Wang DY, Ji XY, Liao QM. Deep learning in nuclear medicine: from imaging to therapy. Ann Nucl Med. 2025. https:\/\/doi.org\/10.1007\/s12149-025-02031-w.","journal-title":"Ann Nucl Med"},{"key":"3346_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics14020181","volume":"14","author":"E Yazdani","year":"2024","unstructured":"Yazdani E, Geramifar P, Karamzade-Ziarati N, Sadeghi M, Amini P, Rahmim A. Radiomics and artificial intelligence in radiotheranostics: a review of applications for radioligands targeting somatostatin receptors and prostate-specific membrane antigens. Diagnostics. 2024;14:1\u201339. https:\/\/doi.org\/10.3390\/diagnostics14020181.","journal-title":"Diagnostics"},{"key":"3346_CR172","doi-asserted-by":"publisher","unstructured":"Ciarmiello A, Mansi L. PET-CT and PET-MRI in neurology: SWOT analysis applied to hybrid imaging, PET-CT and PET-MRI in neurology: SWOT analysis applied to hybrid imaging. 2016. pp. 1\u2013319. https:\/\/doi.org\/10.1007\/978-3-319-31614-7.","DOI":"10.1007\/978-3-319-31614-7"},{"key":"3346_CR173","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/jcb.10405","volume":"64","author":"SZ Lever","year":"2002","unstructured":"Lever SZ. Evolution of radiopharmaceuticals for diagnosis and therapy. J Cell Biochem. 2002;64:60\u20134. https:\/\/doi.org\/10.1002\/jcb.10405.","journal-title":"J Cell Biochem"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03346-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:03:29Z","timestamp":1780430609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03346-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":173,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03346-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}